DR. DAVID C KASLOW, M.D.
Osteopathic Medicine at Kinterra Rd, Wayne, PA
License number
Pennsylvania MD072265L
Category
Osteopathic Medicine
Type
General Practice
Address
Address
15 Kinterra Rd, Wayne, PA 19087
Phone
(267) 663-8173
Personal information
See more information about DAVID C KASLOW at radaris.comName
Address
Phone
1200 Cornerstone Blvd APT 103, Downingtown, PA 19335
1497 Canterbury Ln, Berwyn, PA 19312
15 Kinterra Rd, Wayne, PA 19087
Villanova, PA
611 Fariston Dr, Wynnewood, PA 19096
Professional information
Dr. David C Kaslow, Wayne PA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
15 Kinterra Rd, Wayne 19087
(267) 663-8173 (Phone)
(267) 663-8173 (Phone)
Languages:
English
Education:
Medical School
University of California At San Francisco
Graduated: 1983
University of California At San Francisco
Graduated: 1983
Adenovirus Serotype 26 Vectors, Nucleic Acid And Viruses Produced Thereby
US Patent:
2008025, Oct 16, 2008
Filed:
Feb 7, 2006
Appl. No.:
11/884086
Inventors:
Andrew J. Bett - Lansdale PA, US
Danilo R. Casimiro - Harleysville PA, US
John W. Shiver - Doylestown PA, US
Emilio A. Emini - Wayne PA, US
Michael Chastain - Seattle WA, US
David C. Kaslow - Wayne PA, US
Danilo R. Casimiro - Harleysville PA, US
John W. Shiver - Doylestown PA, US
Emilio A. Emini - Wayne PA, US
Michael Chastain - Seattle WA, US
David C. Kaslow - Wayne PA, US
International Classification:
A61K 39/00, C12N 15/00, C12N 5/06, C12N 15/87, A61P 37/00, C12N 7/00, A61K 35/76, A61K 31/70
US Classification:
4241991, 4353201, 435325, 435455, 4352351, 424 932, 514 44
Abstract:
Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided.
Vaccines For Blocking Transmission Of
US Patent:
7407658, Aug 5, 2008
Filed:
Dec 15, 2006
Appl. No.:
11/611779
Inventors:
David C. Kaslow - Wayne PA, US
Takafumi Tsuboi - Ehime, JP
Motomi Torii - Ehime, JP
Takafumi Tsuboi - Ehime, JP
Motomi Torii - Ehime, JP
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/00, A61K 39/015
US Classification:
4241851, 4242721
Abstract:
The present invention relates novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
Vaccines For Blocking Transmission Of Plasmodium Vivax
US Patent:
2008027, Nov 6, 2008
Filed:
Jul 2, 2008
Appl. No.:
12/167178
Inventors:
David C. KASLOW - Wayne PA, US
Takafumi Tsuboi - Ehime, JP
Motomi Torii - Ehime, JP
Takafumi Tsuboi - Ehime, JP
Motomi Torii - Ehime, JP
Assignee:
The Gov. of the USA as represented by the Secretary of the Dep. of Health and Human Services - Rockville MD
International Classification:
A61K 39/00, C07K 14/00, A61P 37/00, A61K 38/00
US Classification:
4241911, 530350, 514 12
Abstract:
The present invention relates novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.